Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Despina Fotiou

Showing results (31-40 of 108) with videos related to

Pageof 11
Sort By:
Annals of Hematology|May 9, 2020
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year periodEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Roussou, et al.
Clinical and Experimental Medicine|October 31, 2020
Emerging treatment strategies for COVID-19 infectionMaria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Eleni Korompoki, et al.
Vaccines|August 6, 2021
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic EventsEvangelos Terpos, Marianna Politou, Ioannis Ntanasis-Stathopoulos, et al.
Hematological Oncology|March 28, 2023
Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B diseaseFoteini Theodorakakou, Alexandros Briasoulis, Despina Fotiou, et al.
Ejhaem|January 27, 2025
Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myelomaEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
Medicine|November 7, 2019
Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: A case reportMaria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Lia-Angela Moulopoulos, et al.
Annals of Hematology|April 21, 2020
Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myelomaMagdalini Migkou, Irit Avivi, Maria Gavriatopoulou, et al.
Viruses|March 30, 2023
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective StudyVassiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
American Journal of Hematology|July 24, 2022
SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignanciesEvangelos Terpos, Despina Fotiou, Vangelis Karalis, et al.
International Journal of Molecular Sciences|July 29, 2023
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple MyelomaIoannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, et al.
Pageof 11

Showing results (31-40 of 108) with videos related to

Sort By:
Pageof 11
Annals of Hematology|May 9, 2020
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year periodEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Roussou, et al.
Clinical and Experimental Medicine|October 31, 2020
Emerging treatment strategies for COVID-19 infectionMaria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Eleni Korompoki, et al.
Vaccines|August 6, 2021
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic EventsEvangelos Terpos, Marianna Politou, Ioannis Ntanasis-Stathopoulos, et al.
Hematological Oncology|March 28, 2023
Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B diseaseFoteini Theodorakakou, Alexandros Briasoulis, Despina Fotiou, et al.
Ejhaem|January 27, 2025
Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myelomaEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
Medicine|November 7, 2019
Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: A case reportMaria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Lia-Angela Moulopoulos, et al.
Annals of Hematology|April 21, 2020
Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myelomaMagdalini Migkou, Irit Avivi, Maria Gavriatopoulou, et al.
Viruses|March 30, 2023
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective StudyVassiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
American Journal of Hematology|July 24, 2022
SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignanciesEvangelos Terpos, Despina Fotiou, Vangelis Karalis, et al.
International Journal of Molecular Sciences|July 29, 2023
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple MyelomaIoannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, et al.
Pageof 11